Keuangan McKesson Corporation (MCK)
NYSE · Healthcare · Medical - Distribution · Karyawan: 42.300 · CEO: Brian S. Tyler
- Harga
- $994,58 +1,40%
- Kapitalisasi pasar
- $116 M
- Nilai perusahaan
- $122 M
- Laporan terakhir
- Q1 '27 diajukan 2026-08-05
- Laporan berikutnya
- 2026-11-04 Estimasi EPS: $10,72
Pendapatan (TTM)$411 M+8,8% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)1,6%+0,5 poin vs tahun laluLaba operasional: $6,65 M
Laba bersih (TTM)$4,59 M+45,1% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)$6,19 M+9,2% vs tahun laluCapex: $668 jt
EPS dilusian (TTM)$37,37+49,1% vs tahun laluJumlah 4 kuartal terakhir
Kas neto-$6,54 M+13,0% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $116 M EV $122 M
- Pendapatan
- $411 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +7% Konsensus FY2027
- Margin laba
- 1,1% Laba bersih / pendapatan, TTM
- P/E
- 26,5× Forward 22,3× (FY2027)
- P/S
- 0,3× Harga / penjualan, TTM
- EV / EBITDA
- 16,7× TTM
- Arus kas bebas
- $6,19 M 12 bulan terakhir
- Laba bersih
- $4,59 M 12 bulan terakhir
- Estimasi pendapatan
- $432 M Konsensus FY2027
- Laba
- 2026-11-04 Estimasi pendapatan: $110 M
- Dividen
- $3,40 Per saham, 12 bulan terakhir
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-08-05): pendapatan melampaui 1,4%, EPS melampaui 3,9%Pendapatan $105 M vs $104 M yang diharapkan (+1,4%); EPS $9,93 vs $9,56 (+3,9%).
- Pertumbuhan pendapatan melambat: 7,7% yoyPendapatan Q1 '27: $105 M, rata-rata empat kuartal sebelumnya: 12,7%.
- Margin operasional 1,6% (TTM), dibanding tahun lalu: +0,5 poinLaba operasional tumbuh 62,1%, pendapatan tumbuh 8,8%.
- Capex: 0,2% dari pendapatan (tahun lalu 0,2%)$668 jt diinvestasikan dalam 4 kuartal terakhir (-24,2% dibanding tahun sebelumnya). Arus kas bebas: $6,19 M = 134,7% dari laba bersih.
- $5,69 M dikembalikan ke pemegang saham = 92,0% dari arus kas bebasBuyback: $5,3 M (tahun lalu $3,2 M), dividen: $393 jt, kompensasi saham: $0 (TTM).
- Jumlah saham dilusian turun dalam setahun: 5,0%Saham dilusian pada Q1 '27: 119 jt, setahun sebelumnya: 126 jt.
- Utang neto: $6,54 MKas + investasi jangka pendek: $5,16 M, utang termasuk sewa: $11,7 M; tahun lalu utang neto: $7,52 M.
Kuartal terakhir: Q1 '27
Kuartal berakhir 2026-06-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q1 '27 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $105 M | $97,8 M | +7,7% |
| Margin kotor | 3,5% | 3,4% | +0,1 poin |
| Laba operasional | $1,32 M | $1,04 M | +27,3% |
| Margin operasional | 1,3% | 1,1% | +0,2 poin |
| Laba bersih | $614 jt | $784 jt | -21,7% |
| EPS dilusian | $5,15 | $6,25 | -17,6% |
| Arus kas operasional | -$220 jt | -$918 jt | +76,0% |
| Capex | $112 jt | $189 jt | -40,7% |
| Arus kas bebas | -$332 jt | -$1,11 M | +70,0% |
| R&D | $0 | $0 | – |
| Kompensasi berbasis saham | $0 | $0 | – |
Dilaporkan vs konsensus
2026-08-05| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $105 M | $104 M | +1,4% |
| EPS (basis konsensus) | $9,93 | $9,56 | +3,9% |
Dari laporan 2026-08-05 untuk Q1 '27: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q1 '27 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| North American Pharmaceutical Segment | $86,8 M | – | 82,3% | $423 M | – | |
| Oncology And Multispecialty Segment | $14,2 M | – | 13,5% | $62,6 M | – | |
| Medical-Surgical Solutions Segment | $2,82 M | +4,4% | 2,7% | $11,6 M | +1,5% | |
| Prescription Technology Solutions Segment | $1,57 M | – | 1,5% | $7,37 M | – | |
| Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment | – | – | – | – | – |
Pendapatan per wilayah
porsi dari total| Segmen | Q1 '27 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| United States | $47,1 M | +1,7% | 84,6% | $194 M | +7,7% | |
| International Segment | $8,55 M | -9,1% | 15,4% | $37,5 M | -0,6% |
Laba segmen
Laba operasional per segmen pelaporan, dibaca dari catatan segmen setiap 10-Q / 10-K (rincian laba yang tidak ada di sebagian besar data feed).
Segmen pada Q3 '25
| Segmen | Pendapatan | yoy | Laba operasional | yoy | Margin | Margin tahun lalu | Laba operasional TTM |
|---|---|---|---|---|---|---|---|
| US Pharmaceutical Segment | $87,1 M | – | $854 jt | – | 1,0% | – | – |
| International Segment | $3,86 M | – | $111 jt | – | 2,9% | – | – |
| Medical Surgical Solutions Segment | $2,95 M | – | $269 jt | – | 9,1% | – | – |
| Prescription Technology Solutions Segment | $1,37 M | – | $219 jt | – | 16,0% | – | – |
Laba operasional per segmen
kuartalanMargin operasional segmen
kuartalanMargin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- $6,85 M
- Capex
- -$668 jt
- Buyback
- -$5,3 M
- Dividen
- -$393 jt
- Akuisisi
- $609 jt
- Utang neto diterbitkan
- $1,86 M
- Kompensasi berbasis saham
- $0
- Arus kas bebas
- $6,19 M
- Dikembalikan ke pemegang saham / FCF
- 92,0%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | 26,5× | 25,7× | 14,1× – 41,9× |
| EV / EBITDA | 16,7× | 15,1× | 9,6× – 17,7× |
| EV / Penjualan | 0,3× | 0,2× | 0,2× – 0,3× |
| Harga / FCF | 18,7× | 15,8× | 10,9× – 19,8× |
| Harga / Nilai buku | -27,8× | – | – |
| Imbal hasil FCF | 5,3% | 6,7% | 5,1% – 9,2% |
| Imbal hasil modal yang diinvestasikan | 27,9% | 22,1% | 11,5% – 31,5% |
| Imbal hasil ekuitas | -194,4% | -154,2% | -219,2% – -49,0% |
Analis
Target konsensus $983,13 (-1,2%)
rentang $845,00 – $1.200,00 · peringkat Buy
Beli kuat1
Beli24
Tahan6
Jual0
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2027 | $432 M | +7,1% | $44,65 | +16,3% | 22,3× | 9 |
| FY2028 | $461 M | +6,8% | $50,62 | +13,4% | 19,6× | 9 |
| FY2029 | $495 M | +7,2% | $57,93 | +14,4% | 17,2× | 3 |
| FY2030 | $515 M | +4,2% | $66,48 | +14,8% | 15,0× | 1 |
| FY2031 | $560 M | +8,7% | $80,34 | +20,8% | 12,4× | 1 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 282 angka yang ditandai McKesson Corporation dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| – | – | – | -$30 jt | – | – | |
| – | – | – | -0,5% | – | – | |
| – | – | – | $839 jt | – | – | |
| – | – | – | $131 jt | – | – | |
| Accounts Payable, Current | $63,7 M | $57,9 M | +10,1% | $60 M | $55,3 M | +8,4% |
| Accounts Receivable, Allowance for Credit Loss | $194 jt2026-03-31 | $450 jt | -56,9% | $194 jt | $450 jt | -56,9% |
| Accounts Receivable, Allowance for Credit Loss, Current | $259 jt2026-03-31 | $500 jt | -48,2% | $259 jt | $500 jt | -48,2% |
| Accounts Receivable, before Allowance for Credit Loss, Current | $28,2 M2026-03-31 | $26,1 M | +8,0% | $28,2 M | $26,1 M | +8,0% |
| Accounts Receivable, Credit Loss Expense (Reversal) | $45 jt | $196 jt | -77,0% | $100 jt | -$130 jt | +176,9% |
| Accrued Liabilities, Current | $5,04 M | $4,92 M | +2,3% | $5,49 M | $4,83 M | +13,8% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $2,61 M2026-03-31 | $2,53 M | +3,4% | $2,61 M | $2,53 M | +3,4% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$749 jt | -$898 jt | +16,6% | -$745 jt | -$932 jt | +20,1% |
| Additional Paid in Capital | $8,59 M | $8,45 M | +1,6% | $8,28 M | $8,37 M | -1,1% |
| Amortization | $126 jt | $95 jt | +32,6% | $473 jt | $394 jt | +20,1% |
| Amortization of Intangible Assets | $74 jt | $50 jt | +48,0% | $276 jt | $226 jt | +22,1% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1 jt2025-12-31 | 1 jt | 0,0% | 1 jt2025-03-31 | 1 jt | 0,0% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $67 jt | $55 jt | +21,8% | $247 jt | $226 jt | +9,3% |
| Asset Impairment Charges | – | – | – | $0 | $0 | – |
| Assets | $88,3 M | $81,3 M | +8,6% | $82,3 M | $75,1 M | +9,6% |
| Assets, Current | $62,8 M | $56,8 M | +10,6% | $57,2 M | $55,4 M | +3,3% |
| Buildings and Improvements, Gross | $1,45 M2026-03-31 | $1,43 M | +1,3% | $1,45 M | $1,43 M | +1,3% |
| Business Exit Costs | $57 jt | $41 jt | +39,0% | $191 jt | $108 jt | +76,9% |
| Capitalized Computer Software, Accumulated Amortization | $750 jt2026-03-31 | $657 jt | +14,2% | $750 jt | $657 jt | +14,2% |
| Capitalized Computer Software, Amortization | – | – | – | $164 jt | $135 jt | +21,5% |
| Capitalized Computer Software, Net | $764 jt2026-03-31 | $681 jt | +12,2% | $764 jt | $681 jt | +12,2% |
| Cash and Cash Equivalents, at Carrying Value | $5,16 M | $2,42 M | +113,6% | $3,98 M | $5,69 M | -30,2% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $5,26 M | $2,68 M | +95,9% | $4,07 M | $5,96 M | -31,7% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $1,19 M | -$3,27 M | +136,3% | -$1,89 M | $1,37 M | -237,7% |
| Common Stock, Dividends, Per Share, Declared | $0,82 | $0,71 | +15,5% | $3,17 | $2,75 | +15,3% |
| Common Stock, Par or Stated Value Per Share | $0,01 | $0,01 | 0,0% | $0,01 | $0,01 | 0,0% |
| Common Stock, Shares Authorized | 800 jt | 800 jt | 0,0% | 800 jt | 800 jt | 0,0% |
| Common Stock, Shares, Issued | 280 jt | 280 jt | 0,0% | 280 jt | 279 jt | +0,4% |
| Common Stock, Value, Issued | $3 jt | $3 jt | 0,0% | $3 jt | $3 jt | 0,0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $418 jt | $47 jt | +789,4% | $337 jt | $186 jt | +81,2% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $610 jt | $818 jt | -25,4% | $4,95 M | $3,24 M | +52,6% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | $1,03 M | $865 jt | +18,8% | $5,29 M | $3,43 M | +54,1% |
| Construction in Progress, Gross | $578 jt2026-03-31 | $722 jt | -19,9% | $578 jt | $722 jt | -19,9% |
| Contract with Customer, Liability | $366 jt2026-03-31 | $354 jt | +3,4% | $366 jt | $354 jt | +3,4% |
| Cost of Goods and Services Sold | $102 M | $94,5 M | +7,6% | $389 M | $346 M | +12,5% |
| Current Federal Tax Expense (Benefit) | – | – | – | $437 jt | $552 jt | -20,8% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $218 jt | $254 jt | -14,2% |
| Current Income Tax Expense (Benefit) | – | – | – | $872 jt | $988 jt | -11,7% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $217 jt | $182 jt | +19,2% |
| Debt and Lease Obligation | $9,7 M | $7,8 M | +24,4% | $6,5 M | $5,7 M | +14,0% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $248 jt | $102 jt | +143,1% |
| Deferred Foreign Income Tax Expense (Benefit) | $44 jt2026-03-31 | – | – | -$75 jt | -$217 jt | +65,4% |
| Deferred Income Tax Assets, Net | $432 jt2026-03-31 | $367 jt | +17,7% | $432 jt | $367 jt | +17,7% |
| Deferred Income Tax Expense (Benefit) | – | – | – | $230 jt | -$110 jt | +309,1% |
| Deferred Income Tax Liabilities, Net | $1,36 M | $987 jt | +38,1% | $1,33 M | $1,03 M | +29,3% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $57 jt | $5 jt | +1.040,0% |
| Deferred Tax Assets, Gross | $2,64 M2026-03-31 | $2,61 M | +1,3% | $2,64 M | $2,61 M | +1,3% |
| Deferred Tax Assets, Net of Valuation Allowance | $1,88 M2026-03-31 | $1,97 M | -4,6% | $1,88 M | $1,97 M | -4,6% |
| Deferred Tax Assets, Other | $194 jt2026-03-31 | $236 jt | -17,8% | $194 jt | $236 jt | -17,8% |
| Deferred Tax Assets, Tax Credit Carryforwards | $996 jt2026-03-31 | $847 jt | +17,6% | $996 jt | $847 jt | +17,6% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | $333 jt2026-03-31 | $287 jt | +16,0% | $333 jt | $287 jt | +16,0% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts | $69 jt2026-03-31 | $136 jt | -49,3% | $69 jt | $136 jt | -49,3% |
| Deferred Tax Assets, Valuation Allowance | $769 jt2026-03-31 | $644 jt | +19,4% | $769 jt | $644 jt | +19,4% |
| Deferred Tax Liabilities, Gross | $2,77 M2026-03-31 | $2,63 M | +5,6% | $2,77 M | $2,63 M | +5,6% |
| Deferred Tax Liabilities, Inventory | $2,01 M2026-03-31 | $2,14 M | -6,1% | $2,01 M | $2,14 M | -6,1% |
| Deferred Tax Liabilities, Net | $898 jt2026-03-31 | $662 jt | +35,6% | $898 jt | $662 jt | +35,6% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-K 2026-03-31, 10-Q 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-K 2025-03-31, 10-Q 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-01